Progesterone receptor (PROGINS) polymorphism and the risk of endometrial cancer development

International Journal of Gynecological Cancer

Volumn 17, Issue 1, 2007, Pages 229-232

  Junqueira, M G ^a   Da Silva, I D C G ^a   Nogueira De Souza, N C ^a   Carvalho, C V ^a   Leite, D B ^a   Gomes, M T V ^a   Baracat, E C ^a   Lopes, L A F ^b   Nicolau, S M ^a   Goncalves W J ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b HOSPITAL DO SERVIDOR PÚBLICO ESTADUAL DE SÃO PAULO   (Brazil)

Author keywords

Endometrial cancer; Polymorphisms; Progesterone receptor (PROGINS)

Indexed keywords

PROGESTERONE RECEPTOR;

AGED; ARTICLE; CANCER PATIENT; CANCER RISK; CARCINOGENESIS; CASE CONTROL STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; ENDOMETRIUM CANCER; FEMALE; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MYOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN POLYMORPHISM;

AGED; ALLELES; CASE-CONTROL STUDIES; ENDOMETRIAL NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, GENETIC; RECEPTORS, PROGESTERONE;

EID: 33846850518     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00767.x     Document Type: Article

References (27)

1. Ehrlich CE, Young PC, Stehman FB, Sutton GP, Alford WM. Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. Am J Obstet Gynecol 1988;158:796-807.
2. Podratz KC, O'Brien PC, Malkasian GDJ, Decker DG, Jefferies JA, Edmonson JH. Effects of progestational agents in treatment of endometrial carcinoma. Obstet Gynecol 1985;66:106-10.
3. Thigpen T, Blessing J, DiSaia P. Oral medroxyprogesterone acetate in advanced or recurrent endometrial carcinoma. In: Baulieu EE, Iacobelli S, McGuire WL, eds. Endocrinology and Malignancy. Parthenon: New York, 1986:446-54.
4. Fleming GF. Systemic therapy for advanced or recurrent endometrial carcinoma. Curr Oncol Rep 1999;1:47-53.
5. Steiner E, Eicher O, Sagemuller J et al. Multivariate independent prognostic factors in endometrial carcinoma: a clinicopathologic study in 181 patients: 10 years experience at the Department of Obstetrics and Gynecology of the Mainz University. Int J Gynecol Cancer 2003;13:197-203.
6. Gehrig PA, Van Le L. The prognostic value and clinical utility of estrogen and progesterone receptors in endometrial carcinoma. Prim Care Update Obstet/Gynecol 2000;7:55-9.
7. Hirai M, Hirono M, Oosaki T, Hayashi Y, Yoshihara T, Matsuzaki O. Prognostic factors relating to survival in uterine endometrioid carcinoma. Int J Gynaecol Obstet 1999;66:155-62.
8. Salvesen HB, Akslen LA. Molecular pathogenesis and prognostic factors in endometrial carcinoma. Acta Pathol Microbiol Immunol Scand 2002;110:673-89.
9. Punyadeera C, Verbost P, Groothuis P. Oestrogen and progestin responses in human endometrium. J Steroid Biochem Mol Biol 2003;84:393-410.
10. Arnett-Mansfield RL, deFazio A, Wain GV et al. Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium. Cancer Res 2001;61:4576-82.
11. De Vivo I, Huggins GS, Hankinson SE et al. A functional polymorphism in the promoter of the progesterone receptor gene associated with endometrial cancer risk. Proc Natl Acad Sci 2002;99:12263-8.
12. McKenna NJ, Kieback DG, Carney DN, Fanning M, McLinden J, Headon DR. A germline TaqI restriction fragment length polymorphism in the progesterone receptor gene in ovarian carcinoma. Br J Cancer 1995;71:451-5.
13. Agoulnik IU, Tong X-W, Fischer DC et al. A germline variation in the progesterone receptor gene increases transcriptional activity and may modify ovarian cancer risk. J Clin Endocrinol Metab 2004;89:6340-9.
14. Wang-Gohrke S, Chang-Claude J, Becher H, Kieback DG, Runnebaum IB. Progesterone receptor gene polymorphism is associated with decreased risk for breast cancer by age 50. Cancer Res 2000;60:2348-50.
15. Wieser F, Schneeberger C, Tong D, Tempfer C, Huber JC, Wenzl R. PROGINS receptor gene polymorphism is associated with endometriosis. Fertil Steril 2002;77:309-12.
16. Donaldson CJ, Crapanzano JP, Watson JC, Levine EA, Batzer MA. PROGINS Alu insertion and human genomic diversity. Mutat Res 2002;501:137-41.
17. Pearce CL, Hirschhorn JN, Wu AH et al. Clarifying the PROGINS allele association in ovarian and breast cancer risk: a haplotype-based analysis. J Natl Cancer Inst 2005;97:51-9.
18. Rowe SM, Coughlan SJ, McKenna NJ et al. Ovarian carcinoma-associated TaqI restriction fragment length polymorphism in intron G of the progesterone receptor gene is due to an Alu sequence insertion. Cancer Res 1995;55:2743-5.
19. Pijnenborg JMA, Romano A, Dam-de Veen GC et al. Aberrations in the progesterone receptor gene and the risk of recurrent endometrial carcinoma. J Pathol 2005;205:597-605.
20. Tong D, Fabjani G, Heinze G, Obermair A, Leodolter S, Zeillinger R. Analysis of the human progesterone receptor gene polymorphism PROGINS in Austrian ovarian carcinoma patients. Int J Cancer 2001;95:394-7.
21. Lancaster JM, Berchuck A, Carney M, Wiseman RW, Taylor JA. Progesterone receptor gene polymorphism and risk of breast and ovarian cancer. Br J Cancer 1998;78:277.
22. Whittemore AS, Gong G, Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet 1997;60:496-504.
23. Manolitsas TP, Englefield P, Eccles DM, Campbell IG. No association of a 306-bp insertion polymorphism in the progesterone receptor gene with ovarian and breast cancer. Br J Cancer 1997;75:1398-9.
24. Spurdle AB, Webb PM, Purdie DM, Chen X, Green A, Chenevix-Trench G. No significant association between progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of ovarian cancer. Carcinogenesis 2001;22:717-21.
25. Lancaster JM, Wenham RM, Halabi S et al. No relationship between ovarian cancer risk and progesterone receptor gene polymorphism in a population-based, case-control study in North Carolina. Cancer Epidemiol Biomarkers Prev 2003;12:226-7.
26. De Vivo I, Hankinson SE, Colditz GA, Hunter DJA. A functional polymorphism in the progesterone receptor gene is associated with an increase in breast cancer risk. Cancer Res 2003;63:5236-8.
27. Romano A, Lindsey PJ, Fischer DC et al. Two functionally relevant polymorphisms in the human progesterone receptor gene (+331 G/A and progins) and the predisposition for breast and/or ovarian cancer. Gynecol Oncol 2005. In press.